Repligen Corporation is a biopharmaceutical company committed to being the leader in the development of novel therapeutics for the treatment of profound neuropsychiatric disorders, with particular emphasis on applications for children. Our lead product candidate is a synthetic version of the neuroactive peptide secretin for profound social deficits. Secretin is currently in a Phase 2 clinical trial for the treatment of the "negative" (i.e. social) symptoms of schizophrenia and planning is underw...
Search Product